ITC Issues Ban on Infringing Photodynamic Therapy Imports
Published Date: 5/11/2026
Notice
Summary
The U.S. International Trade Commission found that some photodynamic therapy devices and related products imported by certain companies broke patent rules. To fix this, they’re blocking these products from entering the U.S. without permission and ordering the companies to stop selling them. This means affected businesses must act fast or face legal and financial consequences.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Limited Exclusion Order blocking imports
The Commission issued a Limited Exclusion Order (LEO) prohibiting the unlicensed entry into the United States of infringing photodynamic therapy systems, components, and pharmaceutical products that are manufactured by or on behalf of the named respondents or their affiliates. The determination was made by Commission vote on May 6, 2026 and applies to products found to infringe the asserted patents.
Cease-and-desist orders for named respondents
The Commission issued cease-and-desist orders (CDOs) against each named respondent — Biofrontera Inc.; Biofrontera Pharma GmbH; Biofrontera Bioscience GmbH; and Biofrontera AG — requiring them to stop selling the infringing photodynamic therapy systems, components, and related pharmaceutical products. The Commission terminated the investigation after issuing these orders following its May 6, 2026 vote.
Zero percent bond during Presidential review
The Commission set a bond of zero percent (0%) for any importations of the infringing products during the period of Presidential review, under 19 U.S.C. 1337(j). This means importers would not have to post a monetary bond for the covered products during that review period.
Orders suspended for '028 patent pending appeals
The Commission suspended the remedial orders as to U.S. Patent No. 11,697,028 (the '028 patent) in light of a Final Written Decision (FWD) from the Patent Trial and Appeal Board and pending any further action before the Board or potential appeals. The suspension applies while the Board and any appeals remain active.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16811, Certain Ink Cartridges and Components Thereof II; Notice of a Commission Determination Finding a Violation Under Section 337; Issuance of a General Exclusion Order and Cease and Desist Orders; Termination of the Investigation
Notice is hereby given that the U.S. International Trade Commission has determined to find a violation under section 337 of the Tariff Act of 1930, as amended, and to issue a general exclusion order ("GEO") prohibiting the importation of products that infringe claims 1 and 7 of each of the following patents: U.S. Patent Nos. 8,764,172 ("the '172 patent"); 9,370,934 ("the '934 patent"); 11,535,038 ("the '038 patent"); 12,240,248 ("the '248 patent"); and 12,240,249 ("the '249 patent"); and cease and desist orders ("CDOs") against respondents Mountain Peak, Inc. and Straightouttaink, LP. The investigation is terminated.
2026-16816, Hand Trucks and Certain Parts Thereof From China; Determination
2026-16581, Carbazole Violet Pigment 23 From China and India; Termination of Five-Year Reviews
The Commission instituted the subject five-year reviews on May 1, 2026 to determine whether revocation of the countervailing duty order on carbazole violet pigment 23 from India and the antidumping duty orders on carbazole violet pigment 23 from China and India would be likely to lead to continuation or recurrence of material injury. On August 7, 2026, the Department of Commerce published notice in the Federal Register that it was revoking the orders applicable August 7, 2026, because no domestic interested party filed a timely notice of intent to participate. Accordingly, the subject reviews are terminated.
2026-16667, Certain Mobile Electronic Devices; Notice of Institution of Investigation
Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on July 10, 2026, under section 337 of the Tariff Act of 1930, as amended, on behalf of Maxell, Ltd. of Kyoto, Japan. An amended complaint was filed on July 24, 2026. The amended complaint alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain mobile electronic devices by reason of the infringement of certain claims of U.S. Patent No. 10,812,646 ("the '646 patent"); U.S. Patent No. 12,513,408 ("the '408 patent"); U.S. Patent No. 12,061,760 ("the '760 patent"); U.S. Patent No. 12,418,692 ("the '692 patent"); U.S. Patent No. 12,185,211 ("the '211 patent"); and U.S. Patent No. 12,647,935 ("the '935 patent"). The amended complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The amended complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders.
2026-16469, Choline Salts From China; Determinations
The U.S. International Trade Commission found that imports of choline salts from China might be hurting American businesses by being sold unfairly cheap and getting government help. This means a deeper investigation is starting soon, which could lead to new rules or tariffs to protect U.S. companies. If you’re involved in this industry, keep an eye out for updates and possible changes that could affect prices and trade.
2026-16302, Large Vertical Shaft Engines From China; Determinations
Previous / Next Documents
Previous: 2026-09242, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; AVLAYAH (tividenofusp alfa-eknm)
The FDA just gave Denali Therapeutics a special priority review voucher for their rare pediatric disease drug AVLAYAH, approved in March 2026. This voucher speeds up the review of future medicines, helping kids with rare diseases get treatments faster. It’s a big win for patients, the company, and anyone watching rare disease drug development!
Next: 2026-09244, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Testing Communications On Medical Devices and Radiation-Emitting Products
The FDA is asking for public comments on their plan to keep testing how they communicate about medical devices and radiation products. This helps them make sure their messages reach patients, caregivers, and healthcare pros clearly and effectively. Comments are due by June 10, 2026, and this review won’t cost anyone extra but will improve important health info.